参考文献 Anna Wagner, Heike Grabsch, Murielle Mauer, et al. EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: ...
Breast cancer Advances in HER2-targeted treatments have enhanced the survival of patients with HER2-positive breast can- cer [125]. Yet, breast cancer's metastasis to the brain remains a substantial clinical problem, while it can be circumvented with HER2-redirected CAR immuno- therapy [126]. ...
Gastric (stomach) cancer is the fifth most common cancer worldwide and the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease; there were approximately one million new cases reported in 2018 and 783,000 deaths.Incidence rates for gastric cancer a...
Gastric (stomach) cancer is the fifth most common cancer worldwide and the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease; there were approximately one million new cases reported in 2018 and 783,000 deaths.3,4I...
Targeting RNA N6- methyladenosine modification—— a novel therapeutic target for HER2- positive gastric cancerdoi:10.3389/fonc.2024.1387444STOMACH cancerPROGNOSISTREATMENT effectivenessSURVIVAL rateRNAIMMUNOTHERAPYGastric cancer is one of the most common cancers and is considered the ...
Genetic amplification of HER2 drives tumorigenesis and cancer progression in a subset of patients with gastric cancer (GC), and treatment with trastuzumab, a humanized HER2-neutralizing antibody, improves the overall survival rate of HER2-positive patients. However, a considerable portion of the patient...
Gastric (stomach) cancer is the fifth most common cancer worldwide and the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease; there were approximately one million new cases reported in 2018 and 783,000 deaths.3,4In the U.S., it is estimat...
Genetic amplification of HER2 drives tumorigenesis and cancer progression in a subset of patients with gastric cancer (GC), and treatment with trastuzumab, a humanized HER2-neutralizing antibody, improves the overall survival rate of HER2-positive patients. However, a considerable portion of the patient...
Japan has the third highest incidence rate of gastric cancer worldwide, of which approximately one in five cases are considered HER2 positive.[1],[2] For patients with metastatic gastric cancer previously treated with two prior regimens including chemo...
Gastric cancer Gastric (stomach) cancer is the fifth most common cancer worldwide and the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease; there were approximately one mill...